RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Nintedanib Plus Docetaxel Improves PFS and OS for Patients with Stage IIIB/IV or Recurrent Lung Adenocarcinoma
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 14
OP 15
DO 10.1177/155989771306008
UL http://mdc.sagepub.com/content/13/6/14.abstract
AB Nintedanib plus docetaxel significantly improved progression-free survival independent of histology, and prolonged overall survival for non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Adverse events were generally manageable with dose reductions and symptomatic treatment. This article reports on results from the BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in Second-Line Non-Small Cell Lung Cancer study [LUME-Lung 1; NCT00805194; Reck M et al. J Clin Oncol 2013 (suppl; abstr LBA8011)], a placebo-controlled Phase 3 trial of nintedanib plus docetaxel in patients with locally advanced/metastatic NSCLC progressing after first-line therapy.